{"id":"32c2fd7d1ff3","type":"article","url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","title":"IVUS-segmentatiemethoden vergeleken in de PACMAN-AMI-trial","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog"],"tags":["intracoronaire-beeldvorming"],"journal":"Circulation journal : official journal of the Japanese Circulation Society","doi":"10.1253/circj.CJ-25-0590","source_url":"https://doi.org/10.1253/circj.CJ-25-0590","authors":["Nathan Angelo Lecaros Yap","Christos V Bourantas","Sylvain Losdat","Nathaniel Yu Jian Ng","Jonas Häner","Ibrahim Halil Tanboga","Tatsuhiko Otsuka","Yasushi Ueki","Andreas Baumbach","Anthony Mathur","Ryota Kakizaki","Ernest Spitzer","Jouke Dijkstra","Thomas Engstrøm","David Spirk","Irene Lang","Konstantinos C Koskinas","Lorenz Räber"],"significance":4,"published":"2026-04-09","source_date":"2026-03-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This post-hoc analysis of the PACMAN-AMI trial compared two IVUS segmentation methods — conventional 1-mm segmentation versus end-diastolic segmentation — for atherosclerosis measurement accuracy in clinical trials.","created":"2026-07-03T10:32:44Z","updated":"2026-07-03T13:31:40Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In deze post-hocanalyse van de PACMAN-AMI-studie werden twee methoden voor intravasculaire echografie vergeleken: conventionele 1-mm-segmentatie versus eind-diastolische segmentatie. De resultaten zijn relevant voor de nauwkeurigheid van atherosclerosemeting in klinische trials.","abstract_original":"BACKGROUND: This study compared changes in percentage atheroma volume (PAV) using an end-diastolic (ED) intravascular ultrasound (IVUS) segmentation approach vs. the conventional 1-mm interval analysis in serial IVUS data from the PACMAN-AMI trial. METHODS AND RESULTS: IVUS data from the PACMAN-AMI study were analyzed by 2 core laboratories: one with 1-mm segmentation and the other with an ED-based approach. The same arterial segments were assessed at baseline and at the 52-week follow-up in patients receiving alirocumab or placebo. Changes in segment length, lumen, vessel, total atheroma volume (TAV), and PAV between baseline and follow-up were compared between methods. Biomarkers associated with atherosclerotic progression were measured and correlated with TAV and PAV changes. In all, 387 segments were analyzed. Agreement between conventional and ED volumetric analysis was excellent (intraclass coefficient >0.891, P<0.001). TAV and PAV were larger in both groups in the ED analysis than with the conventional approach; however, changes between treatment arms were similar for the conventional and ED analyses (TAV: 14.34 vs. 14.64 mm3, respectively [P=0.823]; PAV: 1.29% vs. 1.25%, respectively [P=0.911]). Biomarker correlations with TAV and PAV changes did not differ between approaches. CONCLUSIONS: ED- and 1-mm-based analyses demonstrated comparable treatment effects of alirocumab on plaque regression in PACMAN-AMI. These findings support the use of the less time-consuming 1-mm segmentation method in serial IVUS studies."}